Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Jones Adrian M

(Last) (First) (Middle)


(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
T2 Biosystems, Inc. [ TTOO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.54 06/07/2019 A 22,000 (2) 06/07/2029 Common Stock 22,000 $0 22,000 I(1)(2) See Footnotes(1)(2)
Explanation of Responses:
1. The Reporting Person is a managing director of Goldman Sachs & Co. LLC ("Goldman Sachs"). Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.
2. The options to purchase 22,000 shares of common stock of T2 Biosystems, Inc. ("Company") were granted to the Reporting Person, pursuant to the Company's Amended and Restated 2014 Incentive Award Plan under the Company's Non-Employee Director Compensation Program, on June 7, 2019 in his capacity as a director of the Company. The options vest and become exercisable in twelve substantially equal monthly installments commencing on June 7, 2019.The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group.
/s/Jennifer Lee, Attorney-in-fact 06/12/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned does hereby make, constitute and appoint each of
Jamison Yardley and Jennifer Lee (and any other employee, of The
Goldman Sachs Group, Inc. (the "Company") or one of its affiliates,
performing the function in connection with which this Power of
Attorney has been granted designated in writing by one of the
attorneys-in-fact), as his true and lawful attorney-in-fact, acting
for him in his respective name, place and stead, whether acting
individually or as a representative of others, to approve, execute
and deliver any documentation required to be made by him under the
Securities Exchange Act of 1934 (as amended, the "Act"), with respect
to securities which may be deemed to be beneficially owned by him
under the Act, such documents to be in such form as such
attorney-in-fact may approve on the undersigned's behalf, such
approval to be conclusively evidenced by the due execution thereof,
and granting unto such attorney-in-fact full power, including
substitution and resubstitution, and authority to act in the premises
as fully and to all intents and purposes as the undersigned might or
could do in person, and hereby ratifies, approves and confirms all
that such attorney-in-fact shall lawfully do or cause to be done by
virtue hereof.

THIS POWER OF ATTORNEY shall remain in full force and effect until
the earlier of (i)
June 11, 2022 and (ii) such time that it is revoked in writing by the
undersigned; provided that in the event the attorney-in-fact ceases
to be an employee of the Company or its affiliates or ceases to
perform the function in connection with which he/she was appointed
attorney-in-fact prior to such time, this Power of Attorney shall
cease to have effect in relation to such attorney-in-fact upon such
cessation but shall continue in full force and effect in relation to
any remaining attorneys-in-fact. The undersigned has the unrestricted
right unilaterally to revoke this Power of Attorney.

This Power of Attorney shall be governed by, and construed in
accordance with, the laws of the State of New York, without regard to
rules of conflicts of law.
IN WITNESS WHEREOF, the undersigned has duly subscribed these
presents as of June 11, 2019.
By: /s/ Adrian Jones
Name: Adrian Jones